Search Results

You are looking at 101 - 110 of 1,396 items for :

  • "carcinoma" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

NCCN Guidelines Updates: Management of Metastatic Kidney Cancer

Eric Jonasch

replace current options in the upfront metastatic setting for clear cell renal cell carcinoma (ccRCC), based on recently reported pivotal trials. Some of these new regimens are not yet incorporated into the NCCN Guidelines, but are expected to be soon

Full access

Complete Response to Erlotinib and Bevacizumab in a Patient With Biphenotypic (Hepatobiliary) Primary Liver Carcinoma

Amy Zhou, Manik Amin, Kathryn J. Fowler, Elizabeth M. Brunt, Jesse Keller, and Benjamin Tan

Biphenotypic (hepatobiliary) primary liver carcinomas [B(H-B)PLCs] are rare tumors representing a heterogenous group of primary liver malignancies with evidence of both biliary and hepatocellular differentiation. These tumors have been referred to

Full access

Metastatic Parotid Gland Carcinoma With ERBB2 Amplification With Complete Response to Fam‐Trastuzumab Deruxtecan

Navika D. Shukla, Ryan S. Chiang, and Alexander D. Colevas

other cancer settings. This includes salivary duct carcinomas (SDCs), which have been commonly linked to the overexpression or amplification of HER2 in gene profiling studies. 1 – 7 More recently, newer second- and third-generation anti-HER2 agents

Full access

Germline PALB2 Variants and PARP Inhibitors in Endometrial Cancer

Michael A. Cilento, Nicola K. Poplawski, Sellvakumaram Paramasivam, David M. Thomas, and Ganessan Kichenadasse

inhibitors to block BER in tumors with HRD results in the accumulation of double-strand breaks and ultimately cell death, the so-called therapeutic synthetic lethality. This report presents a case of recurrent endometrial carcinoma occurring in a patient

Full access

Unanswered Questions in the Management of Stage I-III Merkel Cell Carcinoma

Jonathan S. Zager, Jane L. Messina, L. Frank Glass, and Vernon K. Sondak

/print certificate. Release date: March 10, 2014; Expiration date: March 10, 2015 Learning Objectives Upon completion of this activity, participants will be able to: Identify areas of uncertainty surrounding management of Merkel cell carcinoma

Full access

Role of Surgery for Locally Advanced and Metastatic Renal Cell Carcinoma

Robert Torrey, Philippe E. Spiess, Sumanta K. Pal, and David Josephson

Historically, renal cell carcinoma (RCC) has been a formidable cancer with limited responses to both radiation and systemic management. Currently, surgery offers the only real chance of cure for patients with cancer localized to the kidney and

Full access

Counterpoint: Sentinel Lymph Node Biopsy Is Not Indicated for Ductal Carcinoma In Situ

Stephen B. Edge and David G. Sheldon

ductal carcinoma in situ patients . Ann Surg Oncol 2000 ; 7 : 15 – 20 . 2 Cox CE Nguyen K Gray RJ . Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): Why map DCIS? Am Surg 2001 ; 67 : 513 – 519 . 3 Klauber

Full access

Rediagnosis of Lung Cancer as NUT Midline Carcinoma Based on Clues From Tumor Genomic Profiling

Alexander S. Baras, Jarushka Naidoo, Christine L. Hann, Peter B. Illei, Charles W. Reninger III, and Josh Lauring

(45 U/L). Fiberoptic bronchoscopy was performed with fine-needle aspiration (FNA) of a station 7 lymph node, and the pathology was read as poorly differentiated squamous cell carcinoma (SCC) ( Figure 2 ). Immunostains were positive for p63 and negative

Full access

Current Perspectives on Lymphatic Mapping in Carcinomas of the Uterine Corpus and Cervix

Robert L. Coleman, Michael Frumovitz, and Charles F. Levenback

versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group Study . Gynecol Oncol 1999 ; 72 : 177 – 183 . 12. Burke TW . Treatment

Full access

Point: Interferon-α for Adjuvant Therapy for Melanoma Patients

Michael S. Sabel and Vernon K. Sondak

Interferon-α is possibly the most controversial adjuvant therapy for any solid tumor, and multiple trials involving varying doses, routes, schedules, and formulations of interferon-α have increased the confusion. Clinicians are left in a quandary, because high-dose interferon-α-2b (HDI) remains the only FDA-approved adjuvant therapy for high-risk melanoma. Of the three prospective randomized trials involving high-dose interferon-α-2b, all show a significant improvement in disease-free survival and two show a significant improvement in overall survival. Despite this strong evidence, data from studies involving alternate doses, concerns regarding cost and toxicity, and the promise of future therapies have led opponents of interferon to overlook these results. Based on the available clinical evidence, however, high-dose interferon should be offered as standard care for patients with high-risk, resected melanoma. Informed patients who have elected to forego interferon and patients with lower risk lesions can be offered participation in clinical trials with a no-treatment control arm.